Breakthrough for non invasive glucosse monitoring to be available in 2011?

It seems that echo therapeutics has actually made it and will be making the non invasive glucosse monitor available in the real near futue. This could change all of our lives since we wont have to use needles to poke our fingers

Echo Therapeutics Announces Commercial Launch of Prelude™ on Track

02/08/2011, 7:30 am
Echo Therapeutics Announces Commercial Launch of Prelude™ on Track
Company Receives Comments From FDA That Are Consistent With Expectations

Plans National Exchange Listing and Anticipates Revenue in Third Quarter

FRANKLIN, Mass., Feb. 8, 2011 /PRNewswire/ – Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing the Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude™ SkinPrep System for transdermal drug delivery, today announced that the Company’s partner, Ferndale Pharma Group, LLC, received comments from the U.S. Food and Drug Administration (FDA) on the 510(k) submission of the Prelude SkinPrep System that were deemed minor and were consistent with both companies’ expectations. Echo anticipates that the comments will be addressed quickly and that the planned commercial launch date for the product will remain on track, pending FDA clearance.

As a result of the feedback from the FDA, the Company is now accelerating the final Prelude manufacturing validation and scale-up in order to prepare for commercial launch. Management reiterated its expectation that 2011 will be a transformative year as Echo expects Prelude to receive market clearance and to generate revenues in the third quarter of 2011.

The Company also disclosed today that it has completed the $6.5 million of financing previously announced. Importantly, the Company believes that it now has sufficient funds to substantially complete the development of Symphony. As a result of this and other recent positive developments, Echo plans to apply for listing on a national exchange.

“With a strong balance sheet, much of the Symphony product development work complete, and two strategic partnerships in place, Echo is focused on completing several key milestones during 2011 that will enable the company to begin generating revenue,” commented Patrick T. Mooney, M.D., Chairman and Chief Executive Officer of Echo Therapeutics. “Our primary focus is the successful completion of manufacturing and final product specifications in order to garner FDA clearance of Prelude. We believe that the FDA’s comments will allow us to accelerate our manufacturing scale-up for product validation and product launch in 3Q2011. Additionally, we believe that FDA clearance of Prelude will clear the way for completing additional strategic partner licensing arrangements this year.”

“Through hard work, we believe that we have set the stage for an exciting and productive 2011,” Dr. Mooney continued. “We look forward to working with Ferndale to grow the topical anesthetic market in the US and generate cash flow for Echo in 2011. Additionally, we plan to have the final Symphony System, which includes Prelude, ready in 2Q11 and begin final testing at that time. We believe that we are positioned to be ‘first-to-market’ with tCGM in the hospital critical care market. We estimate that the hospital market opportunity for continuous glucose monitoring is greater than $1 billion. In addition, we plan to develop the Symphony System for use in the consumer market, providing additional upside potential and partnership possibilities in this more than $12 billion market opportunity.”

that’s great news but now how am I going to get my daily dose of my own blood?

Thanks for drawing my attention to what appears to be a imminent release of a new continuous glucose monitor that utilizes new technology. While using a transdermal patch to sense changes in “analytes” as an indirect method of measuring blood glucose, I only hope that this new technology improves the accuracy and precision of today’s CGMs.

While current CGMs are great at displaying trends, they suffer from using calibration standards (current finger-stick meters) known for their inaccuracy. Most finger-stick meters today suffer from a weak +/- 15% performance.

I for one wouldn’t mind paying more for a meter that is more accurate and precise. I continuously make dosing decisions that not only affects my long-term health but in the short-term is potentially fatal. It’s kind of like driving a car at high speed with a steering wheel known for its unpredictable response!

here is a reference to the study of accuracy

Great news! This will be ready for the CONSUMER market in 2011? Can’t wait… this will be life changing

On a visit to the endo. a few months back (before pump), my meter at the time (One Touch Ultra Smart) varied from the one the doctor’s office used by 86 points! That’s the whole acceptable range! I was told they lose accuracy over time, and they handed me a new One Touch Ultra. I have 2 newer One Touch Ultras and a One Touch Ultra Link, but have never used all 3 with the same blood to see their variance.

On topic: I skimmed the links, but not very in depth. Is this a new CGM that doesn’t have a needle/probe? That would be fantastic.

I am a stock trader too. Just checking, the stock was @ 86 cents a share and is now @ 4.29 a share with a huge rise in January. If this takes and they get approval from the FDA I suspect they will be bought out by another larger company in the future. Definitely now on my watch list.

It sounded to me like they were going to put it in the hospital setting first and then transition to home use.

This is exciting news, especially as I’m not yet on a CGM but have been leaning that way a bit in the past few months…

If I understand it right, this CGM’s accuracy is as good as fingersticking (12.89% vs 15%). We could throw out our meters and get readings every minute! Wow, double wow, if cost and usability work out.

I guess you could have patch pumps using transdermal infusion instead of a cannula. Maybe faster absorption of insulin and no risk of scarring?

Any idea what this system looks like?

My doctor was telling me on Monday about an implant under development that was more like a pacemaker, implanted in your upper chest, that would give continuous readings from your bloodstream and that these have been very, very accurate in tests (much more accurate than current meters or current CGM).

Is this the same thing?

Nope. Not the same. ;0)

LOL - Down auto-vampire boy, down.

Did you doctor mention the name of it:?